Speaker Profile

M.D., Ph.D., Professor of Medicine, UT - MD Anderson

Dr. Tsimberidou has designed highly innovative clinical trials that have changed the standard of practice of oncology in patients with solid tumors and hematologic malignancies. She pioneered the personalized medicine program for advanced cancer at MD Anderson Cancer Center, demonstrating that identification of molecular aberrations and selection of therapy based on tumor abnormalities is associated with improved clinical outcomes compared with standard approaches. She is leading IMPACT2, a randomized trial in precision oncology, and personalized immunotherapy trials. She has published >280 articles in high-impact peer-reviewed journals. She has been invited to present her work as a keynote speaker at numerous national and international conferences. She has received various prestigious awards including a Career Development Award from ASCO. She chaired ASCO’s Clinical Research Committee (2016-2017) and serves on various ASCO committees. Her high-quality innovative research focuses on development and implementation of precision oncology through innovative therapeutic approaches, education, and patient care.

Implementation of Precision Oncology in Advanced Cancer
In 2007, we initiated the personalized medicine program for patients with advanced cancer. We used tumor molecular profiling to optimize selection of investigational targeted therapies and demonstrated that this approach was associated with favorable outcomes. Although several gaps still exist, personalized oncology holds the promise to improve clinical outcomes.

 Session Abstract – PMWC 2023 Silicon Valley

Track 4 - January 26 9.00 A.M.-4.30 P.M.

Track Chair: Cindy Perettie, Roche

  • PMWC 2023 Award Ceremony
    - Luis Alberto Diaz Jr., MSK
    - Razelle Kurzrock, Medical College of Wisconsin
  • Non-invasive Liquid Biopsy Techniques (PANEL)
    Chair: Razelle Kurzrock, Medical College of Wisconsin
    - Apostolia Tsimberidou, MD Anderson
    - Mandana Kamgar, MD Medical College of Wisconsin
    - Mina Nikanjam, UCSD
    - Ash Alizadeh, Stanford University
  • Liquid Biopsy Challenges and Limitations (PANEL)
    Chair: Victor Lin, Mary Bird Perkins
    - Luis Alberto Diaz Jr., MSK
    - Maximilian Diehn, Stanford
    - Dana Dilbeck, Agilent
    - Emma Shtivelman, Cancer Commons
  • Liquid Biopsy in Clinical Trials: Learnings and COVID Experience (PANEL)
    Chair: Cindy Perettie, Roche Diagnostics
    - Eric Peters, Genenetch
    - Andrew Mckenzie, Sarah Cannon
    - Yang Pan, Gilead
    - Alan Sandler, Mirati Therapeutics
  • Multi-Cancer Early Detection Through Multi-Biomarker Class Liquid Biopsy Testing
    Chair: Tom Beer, Exact Sceinces
  • Liquid Biopsy for Early Cancer Detection (PANEL)
    Chair: Priti Hegde, Foundation Medicine
    - Daniel Kim, UCSC
    - Mike Nolan, Freenome
    - Jeffrey Venstrom, Grail Bio
    - Kathryn Phillips, UCSF
    - Lon Castle, eviCore healthcare
    - Tom Beer, Exact Sciences
  • Liquid Biopsy for Minimal Residual Disease (PANEL)
    Chair: Minetta Liu, Natera
    - Peter Bach, Delfi diagnostics
    - Laura Vantveer, UCSF
    - Susan Bobulsky, Adaptive
    - Joshua Cohen, Johns Hopkins
  • PMWC Showcase
    - Harmeet Dhani, Biological Dynamics
    - Varsha Rao, Claret Bio
  • PMWC NCI Showcase
    - Xianghong Jasmine Zhou, EarlyDiagnostics